The Development and Characterization of a Next-Generation Oncolytic Virus Armed with an Anti-PD-1 sdAb for...

Area of Science:

• Oncolytic virotherapy
• Immunotherapy
• Cancer biology

Background:

• Osteosarcoma (OS) is an aggressive bone cancer with poor prognosis and limited treatment options.
• Conditionally replicative adenoviruses (CRAds) offer potential for targeted cancer therapy.
• Combining CRAds with immune checkpoint inhibitors may enhance anti-tumor efficacy.

Purpose of the Study:

• To investigate the anti-tumor efficacy of CAV2-AU-M2, a CRAd armed with an anti-PD-1 single-domain antibody (sdAb), against osteosarcoma cell lines.
• To evaluate the selective replication, cell lysis, and cytotoxicity of CAV2-AU-M2 in vitro.
• To assess the binding capability of the produced anti-PD-1 sdAb.

Main Methods:

• Testing CAV2-AU-M2 infection, replication, and cytopathic effects in four OS cell lines using 2D and 3D cultures.
• Assessing cytotoxicity of CAV2-AU-M2 against OS cells.
• Confirming the production and binding of the anti-PD-1 sdAb to PD-1 receptors.

Main Results:

• CAV2-AU-M2 demonstrated selective replication in osteosarcoma cells.
• The CRAd effectively induced tumor cell lysis and death.
• The produced anti-PD-1 sdAb showed effective binding to PD-1 receptors.

Conclusions:

• CAV2-AU-M2 is the first CRAd armed with an anti-PD-1 sdAb, demonstrating potent anti-osteosarcoma activity in vitro.
• This dual immunotherapy approach holds promise for enhancing anti-tumor immune responses.
• Further research is warranted to explore its therapeutic potential in vivo.